Neurogene (NGNE) Profit After Tax (2013 - 2026)
Neurogene's (NGNE) quarterly Profit After Tax came in at -$30.9 million in Q1 2026, down 36.59% YoY from -$48.8 million in Q1 2025, and down 24.73% on a QoQ basis from -$24.8 million in Q4 2025.
Neurogene (NGNE) Profit After Tax (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Profit After Tax data on file, last reported at -$30.9 million in Q1 2026.
- Quarterly Profit After Tax fell 36.59% year-over-year to -$30.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.7 million (down 22.05% YoY) and the FY2025 annual result came in at -$90.4 million, down 20.3% from the prior year.
- Profit After Tax retreated to -$30.9 million in Q1 2026, from -$24.8 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $13.7 million in Q4 2023 to a low of -$49.8 million in Q4 2022.
- A 5-year average of -$18.6 million and a median of -$18.5 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax surged 127.4% — and 2024, when it plunged 242.92%.
- Tracing NGNE's Profit After Tax over 5 years: stood at -$49.8 million in 2022, then soared by 127.4% to $13.7 million in 2023, then sank by 242.92% to -$19.5 million in 2024, then retreated by 27.09% to -$24.8 million in 2025, then retreated by 24.73% to -$30.9 million in 2026.
- The last three Profit After Tax figures came in at -$30.9 million (Q1 2026), -$24.8 million (Q4 2025), and -$21.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | -34.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.49 Mn |
| Mar 31, 2026 | -30.93 Mn |
| Dec 31, 2025 | -24.80 Mn |
| Sep 30, 2025 | -20.95 Mn |
| Jun 30, 2025 | -22.02 Mn |
| Mar 31, 2025 | -22.65 Mn |
| Dec 31, 2024 | -19.51 Mn |
| Sep 30, 2024 | -20.22 Mn |
| Jun 30, 2024 | -18.49 Mn |
| Mar 31, 2024 | -16.92 Mn |
| Dec 31, 2023 | 13.65 Mn |
| Sep 30, 2023 | -14.58 Mn |
| Jun 30, 2023 | -11.86 Mn |
| Mar 31, 2023 | -12.26 Mn |
| Dec 31, 2022 | -49.84 Mn |
| Sep 30, 2022 | -13.07 Mn |
| Jun 30, 2022 | -15.69 Mn |
| Mar 31, 2022 | -15.35 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -15.45 Mn |